Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Vince A. Miller"'
Autor:
Jeffrey S. Ross, Siraj M. Ali, Omotayo Fasan, Jared Block, Sumanta Pal, Julia A. Elvin, Alexa B. Schrock, James Suh, Sahar Nozad, Sungeun Kim, Hwa Jeong Lee, Christine E. Sheehan, David M. Jones, Jo-Anne Vergilio, Shakti Ramkissoon, Eric Severson, Sugganth Daniel, David Fabrizio, Garrett Frampton, Vince A. Miller, Philip J. Stephens, Laurie M. Gay
Background Genomic fusions of the anaplastic lymphoma kinase gene (ALK) are a well-established therapy target in non-small cell lung cancer (NSCLC). From a survey of 114,200 clinical cases, we determined the prevalence of ALK rearrangements (rALK) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31f95571cd455d60ceb719e86d64a164
https://europepmc.org/articles/PMC5728036/
https://europepmc.org/articles/PMC5728036/
Autor:
X.J. Cong, Diane L. Fairclough, James Chih-Hsin Yang, Mike K. Palmer, Vince A. Miller, Robert M. Lorence, Vera Hirsh, Jacques Cadranel, Henrik W. Finnern
Publikováno v:
Journal of Thoracic Oncology. 8:229-237
BackgroundPatient-reported symptom and health-related quality of life (HRQoL) benefit of afatinib, a novel, irreversible, ErbB Family Blocker, was investigated in a double-blind, randomized, phase IIb/III trial (LUX-Lung 1).MethodsFive hundred and ei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd7b2b7980564b8cf7fbeddb899920d3
https://doi.org/10.1097/jto.0b013e3182773fce
https://doi.org/10.1097/jto.0b013e3182773fce
